|
|
|
| Diagnostic value of combined detection of tumor markers in lung cancer |
| XIE Chaohui1 FANG Kun2▲ |
1.Department of Laboratory, Chengdu First People′s Hospital, Sichuan Province, Chengdu 610041, China;
2.Department of Laboratory, Sichuan Science City Hospital, Sichuan Province, Mianyang 621900, China |
|
|
|
Abstract Objective To investigate the diagnostic value of combined detection of carcinoembry onic antigen (CEA), neuron-specific enolase (NSE), cytokeratin-19-fragment (CYFRA21-1), pro-gastrin-releasing peptide (ProGRP), and squamous cell carcinoma antigen (SCC-Ag) in lung cancer. Methods A total of 158 patients with lung cancer in the Chengdu First People′s Hospital from January to December 2017 were selected as lung cancer group(there were 51 cases of squamous cell carcinoma group, 72 cases of adenocarcinoma group and 35 cases of small cell carcinoma group), and 50 healthy persons during the same period were selected as health group. The levels of CEA, NSE, CYFRA21-1, ProGRP, and SCC-Ag in serum were detected respectively. Logistic regression receiver operating characteristic curve were applied to analyze the data and evaluate the diagnostic values. Results The concentrations of CEA, NSE, CYFRA21-1, ProGRP and SCC-Ag in lung cancer group were significantly higher than those in the healthy group (P < 0.01). The serum levels of NSE and ProGRP were the highest in small cell carcinoma group. The concentration of CEA was the highest in adenocarcinoma group, while that of SCC-Ag and CYFRA21-1 in squamous cell carcinoma group. The levels of five markers in lung cancer patients with stage Ⅲ-Ⅳ were significantly higher than those with stage Ⅰ-Ⅱ, the differences were statistically significant (P < 0.01). The area under the curve of combined detection Logistic regression model was 0.925, which was significantly higher than that of single test. Conclusion The combined of 5 serum tumor markers can improve the accuracy of lung cancer diagnosis.
|
|
|
|
|
|
[1] 周艳珍，李红霞，李爱华，等.多种肿瘤标志物联合诊断肺癌的价值分析[J].疑难病杂志，2018，17（1）：18-21.
[2] 王靖妍，尹扬，赵知明.肺癌血清标志物在健康体检中的价值分析[J].癌症进展，2018，16（1）：110-112，119.
[3] 龚玉芳，刘峰，杨志胤，等.新辅助化疗前后非小细胞肺癌患者血清CA125、CEA及CYFRA21-1的变化及预后分析[J].中国医药导报，2017，14（11）：91-94.
[4] 卢兴兵，石佳，李勤，等.血清肿瘤志物在诊断转移性肺癌中的临床价值[J].检验医学与临床，2018，15（2）：179-182.
[5] 陈良安.肺癌早期诊断新技术及临床评价[J].中华医学信息导报，2017，32（19）：21.
[6] 姚齐龙，刘晓雄，谢萍，等.多种肿瘤标记物检测在肺癌诊断中的意义[J].医学临床研究，2016，33（9）：1796-1797， 1800.
[7] 陈一超，辇伟奇，冉静，等.肿瘤标志物联合检测对肺癌诊断、病理分型和临床分期的临床价值[J].国际检验医学杂志，2018，39（1）：32-37.
[8] 丁锋，张清会.血清神经元特异性烯醇化酶、乳酸脱氢酶在小细胞肺癌组织中的表达及意义[J].实用医院临床杂志，2018，15（1）：121-123.
[9] 沈红良，李娜.肺癌患者血清HE4、CEA、NSE水平变化及临床诊断价值[J].检验医学与临床，2018，15（1）：109-112.
[10] 王爱红，王明全，周小燕，等.血清肿瘤标志物对于原发性支气管肺癌病理类型的判别分析[J].中国医药导报，2017，14（23）：67-70.
[11] 杨卫京，牛东，王辉.肺癌患者化疗前后血清CYFRA21-1、NSE和CA125水平的变化及意义[J].医学综述，2017， 23（20）：4150-4153.
[12] 任芳萍，蒋延文.支气管肺泡灌洗液中肿瘤标记物检测对肺癌诊断的应用价值[J].诊断病理学杂志，2017，24（10）：774-777.
[13] 段桦，崔慧娟，彭艳梅，等.神经元特异烯醇化酶、胃泌素释放肽前体与小细胞肺癌病情变化的相关性研究[J].中日友好医院学报，2017，31（5）：279-282.
[14] 赵云龙.胃泌素释放肽前体对小细胞肺癌诊治的临床意义及病例报告[D].北京：北京协和医学院，中国医学科学院，2016.
[15] 薛珊，查琼芳，赵旭霁，等.CEA、CA125、CYFRA21-1、NSE和SCC对非小细胞肺癌化疗效果及进展评估的价值[J].山东医药，2015，55（25）：8-11.
[16] 吴园园，管世鹤，杨凯，等.血清肿瘤标志物在肺癌辅助诊断中的应用[J].中国微生态学杂志，2017，29（5）：547-549.
[17] 倪军，郭子健，张力，等.单独与联合检测四项肺癌血清肿瘤标志物在肺癌诊断中的价值[J].中华内科杂志，2016， 55（1）：25-30.
[18] 戎荣，程义壮，沈佐君.四种血清肿瘤标志物联合检测在肺癌诊断中的价值[J].山东医药，2018，58（1）：78-80.
[19] 张莉娜.含截尾数据的时间依依的ROC曲线分析[J].中国卫生统计，2014，31（5）：867-869.
[20] 秦正积，沈毅，崔晓莉，等.Logistic回归在疾病多指标联合诊断中的应用[J].中国卫生统计，2014，31（1）：116-117. |
|
|
|
